CARA News and Press, Cara Therapeutics Inc. From 02/04/21

Cannabis stocks could see new highs this year. Fueling momentum, Jazz Pharmaceuticals (NASDAQ:JAZZ) said it would acquire GW Pharmaceuticals (NASDAQ:GWPH) to help strengthen its neuroscience business with GWPH’s cannabis-based epilepsy treatment. That also set in motion stren...

Cara Therapeutics (CARA) announces the start of Phase 2 trial of Oral KORSUVA (difelikefalin) for the treatment of moderate-to-severe pruritus in patients suffering from notalgia paresthetica, a nerve disorder characterized by chronic pruritus of the upper to middle back.This 8...

STAMFORD, Conn., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced t...

STAMFORD, Conn., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today an...

Cara Therapeutics (CARA) has submitted a New Drug Application to the FDA for KORSUVA™ Injection (difelikefalin) for the treatment of moderate-to-severe pruritus in hemodialysis patients.KORSUVA has the FDA's Breakthrough Therapy Designation for the indication, and with Priori...

First NDA submission for Company’s lead program, KORSUVA™ Injection – NDA submission includes request for Priority Review under Breakthrough Therapy Designation for KORSUVA Injection – STAMFORD, Conn., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Car...

SWK Holdings' (SWKH) wholly-owned subsidiary, Enteris BioPharma received a second milestone payment of $2.5M from Cara Therapeutics (CARA) with regards the license agreement for Peptelligence oral formulation technology utilized in Oral KORSUVA.According to the contractual splits ag...

SWK Holdings' Subsidiary, Enteris BioPharma, Receives Second Milestone Payment from Cara Therapeutics Second milestone payment related to the development of Oral KORSUVA™ follows initial $2.5 million milestone payment received in October PR Newswire DALLAS ...

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® technology platform, today announ...

The opioid industry is an ~$50 billion annual business, but opioids are very harmful to the body and extremely addictive. CARA has a drug that is finishing its trials and expectation is that an NDA will be filed shortly, paving way for New Drug status and the ability to distribute. ...